ArticleMedical physics2025
Machine learning prediction-informed gaze optimization in ocular proton therapy with NTCP evaluation.
Article in Medical physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Machine learning prediction-informed gaze optimization in ocular proton therapy with NTCP evaluation.Medical physics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundOcular proton therapy (OPT) treatment planning has remained largely static since the introduction of the EyePlan system over four decades ago, which is still widely used across treatment centers. The current method relies on planners individually selecting gaze fixation points to optimize eye orientation, aiming to minimize the exposure to sensitive sensitive ocular organs at risk (OARs). However, this manual process lacks explicit information on how eye orientation correlates with toxicity risks. This limitation presents an opportunity to enhance planning efficiency, reduce planner biases, and provide toxicity-informed guidance through automated computational tools. PURPOSE: The primary objective of this research is to develop a computationally efficient automated approach for OPT treatment planning that optimizes eye orientation during treatment. By providing intuitive and clinically relevant information to treatment planners, the approach aims to minimize healthy tissue exposure and reduce the risk of radiation-induced toxicities.
methodDose calculations are conducted using the in-house developed treatment planning system (OCULARIS) guided by machine learning (ML) gaze predictions and a tailored cost-function that allows to quickly identify eye orientations with favorable healthy tissue sparing suitable for treatment. The orientations identified by the optimization algorithm are subsequently evaluated against the clinically defined orientations, utilizing both cost metrics and recent normal tissue complication probability (NTCP) models, acknowledging the inherent uncertainties associated with these models. The resulting plans are then validated and evaluated by two clinically experienced medical physicists.
resultsIn 92% of patient cases, the automated plans were found to be preferable or comparable to the clinical plans, with 25% rated as preferable. In 67% of cases, the automated plan demonstrated comparable toxicity levels to the clinical plan. Additionally, 47% of cases showed that the automated plans achieve at least a 1% improvement in one of the investigated NTCPs without significantly impacting the others.
conclusionsThis work signifies a more informed strategy for OPT treatment planning, enhancing both speed and automation while reducing planner biases. The methodology offers treatment planners with direct and intuitive information correlating the orientation of the treated eye with toxicity risks. Our investigation considering the direct application of NTCP models demonstrates that eye orientations for OPT could be automatically generated with a comparable or superior treatment suitability for the 92% of investigated patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.